Flexion Therapeutics

Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.

WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical com

Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer

NEW ORLEANS, Nov. 2, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

FLEXION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN

Dawson Geophysical

PAE Inc

Acceleron Pharma

NEW YORK, Nov. 1, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Dawson Geophysical Company (NASDAQ: DWSN) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dawson Geophysical Company (NASDAQ: DWSN) in connection with the proposed acquisition of DWSN by a subsidiary of Wilks Brothers, LLC.

SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations

NEW YORK, Oct. 30, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Flexion Therapeutics, Inc. ("FLXN" or the "Company") (FLXN) relating to its proposed acquisition by Pacira BioSciences, Inc. Under the terms of the agreement, FLXN shareholders will receive $8.50 in cash per share they own. The investigation focuses on whether Flexion Therapeutics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXN

Adamas Pharmaceuticals

FTS Int.

Umpqua Holdings

NEW YORK, Oct. 28, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: FTS International, Inc. (NYSE: FTSI)  concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ProFrac Holdings, LLC for $26.52 per share in cash. If you are an FTS International shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Flexion Therapeutics (FLXN) Q3 Earnings Expected to Decline

Aspen Technology Inc

Eagle Bancorp Montana

NEW YORK, Oct. 26, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) in connection with the proposed acquisition of the company by Supernus Pharmaceuticals, Inc.  Under the terms of the agreement, ADMS shareholders will receive $8.10 per share in cash, plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, payable upon achieving certain net sales thresholds of ADMS's lead product, GOCOVRI, for each share of ADMS stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations

On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.

Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?

Flexion Therapeutics recently announced that they have agreed to be acquired by Pacira BioSciences for $8.50 a share bid with the potential for an extra $8 from CVR. I provide a brief background on Pacira BioSciences and some of the details of the deal.

Flexion Therapeutics: Bullish On The Buyout

Pacira Pharmaceuticals

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Flexion Therapeutics, Inc. ("Flexion" or the "Company") (NASDAQ: FLXN) in connection with the proposed acquisition of the Company by Pacira BioSciences, Inc. ("Pacira") (NASDAQ: PCRX).  Under the terms of the merger agreement, Pacira will commence a tender offer to acquire all outstanding shares of Flexion for a purchase price of $8.50 per share in cash, plus one non-tradeable contingent value right ("CVR").

SHAREHOLDER ALERT: WeissLaw LLP Investigates Flexion Therapeutics, Inc.

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. (NASDAQ: FLXN) and its board of directors concerning the proposed acquisition of the company by Pacira BioSciences, Inc. (NASDAQ: PCRX). Stockholders will receive $8.50 and one contingent value right worth up to $8.00 for each share of Flexion Therapeutics stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc.

New York, New York--(Newsfile Corp. - October 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Flexion Therapeutics, Inc. (NASDAQ: FLXN) ("Flexion Therapeutics" or the "Company") stock prior to October 11, 2021. To view an enhanced version of this graphic, please visit:

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Flexion Therapeutics, Inc. with Pacira BioSciences, Inc.

MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Flexion (Nasdaq: FLXN), for possible breaches of fiduciary duty and other violations of law in its transaction with Pacira. Click here to learn how to join the action: https://www.ademilaw.com/case/flexion-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Flexion Therapeutics, Inc. has obtained a Fair Price in its transaction with Pacira

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Flexion Therapeutics, Inc. (NASDAQ: FLXN) to Pacira BioSciences, Inc. for $8.50 per share in cash plus one non-tradeable contingent value right worth up to $8.00 per share in cash is fair to Flexion shareholders. Halper Sadeh encourages Flexion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060

Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN

Pacira BioSciences Inc (NASDAQ: PCRX) has agreed to acquire Flexion Therapeutics Inc (NASDAQ: FLXN) for $8.50 per share in cash, plus one contingent value right (CVR) worth up to $8.00 per share in cash.  Pacira ended Q2 of 2021 with cash, cash equivalents, and short-term investments of $646.6 million.

Pacira Beefs Up Non-Opioid Pain Management Via Flexion Acquisition

The stock price of Flexion Therapeutics Inc (NASDAQ: FLXN) increased by over 65% pre-market today. This is why it happened.

FLXN Stock: Why It Substantially Increased Today

Tampa, Fla.-based Pacira BioSciences Inc. PCRX, -1.34% said Monday it is acquiring Flexion Therapeutics Inc. FLXN, +2.30% , based in Burlington, Mass.

Flexion Therapeutics shares soar 39% premarket on news to be acquired by Pacira Biosciences

-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

BURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 1, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 4:35 p.m. ET on Thursday, September 9, 2021.

Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference

BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice guidelines for the management of osteoarthritis (OA) of the knee.1

Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee

Flexion Therapeutics (FLXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Flexion Therapeutics (FLXN) Upgraded to Buy: Here's What You Should Know

Flexion Therapeutics Inc (NASDAQ: FLXN) expanded the Phase 1b trial of FX301 in patients undergoing bunionectomy.  Related:   Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery.

Why Is Flexion Therapeutics (FLXN) Stock Gaining On Wednesday?

BURLINGTON, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in patients undergoing bunionectomy. FX301 is a novel formulation of a locally administered NaV1.7 inhibitor (funapide) which aims to provide at least three to five days of post-operative pain relief while preserving motor function. The company's decision to advance FX301 into the expansion cohort follows a review of safety data from the single ascending dose stage of the trial by an independent Safety Monitoring Committee. Subsequently, an internal review committee assessed safety, systemic exposure and efficacy data and made the decision to advance the program.

News for Flexion Therapeutics Stock (FLXN)